Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023)
Alto Neuroscience (ANRO) posted Net Equity Issued and Repurchased of $45.0 million for Q4 2023, up 80.0% sequentially from $25.0 million in Q1 2023.
Powered by 
Analysis
Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023) Analysis & Trends
Alto Neuroscience has reported Net Equity Issued and Repurchased for 1 years, with the latest figure at $45.0 million in Q4 2023.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $45.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $45.0 million (changed N/A YoY) and the FY2023 annual result came in at $70.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $45.0 million in Q4 2023 per ANRO's latest filing, from $25.0 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $45.0 million in Q4 2023 and troughed at $25.0 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | - |